Tempest Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 0.00 shares, a 100.00% decline from fiscal 2024.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 6.28K shares, a 781.35% increase from fiscal 2023.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 713.00 shares.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 0.00 shares, a 100.00% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-14 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 0.00 shares 10-K · filed 2026-03-30 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2026-05-14 | 0.00 shares derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 6.28K shares 10-K · filed 2026-03-30 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 6.58K shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 6.58K shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | 6.28K shares 10-Q · filed 2025-05-13 | 7.00K shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | 300.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 713.00 shares 10-K · filed 2025-03-27 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 413.00 shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | 413.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 413.00 shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2024-05-09 | 0.00 shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | 0.00 shares 10-K · filed 2024-03-19 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 7.26K shares derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 22.47K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | 0.00 shares 10-Q · filed 2023-05-10 | 28.76K shares derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | 7.26K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | 33.13K shares 10-K · filed 2023-03-22 |
| 2021-09-30 | 15.22K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 38.83K shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | 6.29K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 23.61K shares derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | 4.37K shares 10-Q · filed 2022-05-13 | 18.77K shares derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | 12.96K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 14.41K shares 10-K · filed 2022-03-29 |
| 2020-09-30 | 0.00 shares 10-Q · filed 2020-11-09 | 1.45K shares derived: sum of 4 quarters · filed 2021-05-13 |
| 2020-06-30 | 1.45K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | 52.73K shares derived: sum of 4 quarters · filed 2021-05-13 |
| 2020-03-31 | 0.00 shares 10-Q · filed 2021-05-13 | 97.22K shares derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | 97.22K shares 10-K · filed 2021-03-29 |
| 2019-09-30 | 51.28K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | |
| 2019-06-30 | 45.95K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | |
| 2019-03-31 | 0.00 shares 10-Q · filed 2019-05-15 | |
| 2018-12-31 | 0.00 shares 10-K · filed 2020-03-11 | |
| 2017-12-31 | 608.00 shares 10-K · filed 2019-04-01 | |
| 2016-12-31 | 63.99K shares 10-K · filed 2017-03-02 | |
| 2015-12-31 | 208.75K shares 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |